A phase 2b study for histological assessments has been initiated, and it aims to evaluate the treatment effects of the hepatic silencing of PNPLA3 on histological MASH and liver fibrosis in patients with the PNPLA3 148M risk allele variant [41]. The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatohepatitis.